GlassScriptPhysician profile
Namrita Baveja
NPI 1164678744
$4,212.86
in general payments reported to CMS, 2019-2025
35 companies · $794 in 2025
The $794 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $228 · 2021: $382 · 2022: $720 · 2023: $728 · 2024: $1,118 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,395 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,394.51 |
| Education | $245.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $659.85 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Mallinckrodt Hospital Products INC. | $576.05 | 2020-2025 | Acthar, Terlivaz |
| Travere Therapeutics, INC. | $382.50 | 2023-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $374.62 | 2021-2025 | |
| Vifor Pharma, INC. | $368.76 | 2019-2023 | Korsuva, Veltassa |
| Akebia Therapeutics INC | $254.79 | 2019-2025 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $242.56 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $177.36 | 2021-2025 | Lokelma, Farxiga |
| Amgen INC. | $168.01 | 2019-2024 | Parsabiv, Aranesp, Tavneos |
| Opko Pharmaceuticals, LLC | $157.50 | 2019-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $146.01 | 2022-2023 | Benlysta |
| Ani Pharmaceuticals, INC. | $62.97 | 2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $57.24 | 2024-2025 | Wegovy, Ozempic |
| Axonics, INC. | $51.81 | 2021 | |
| Novartis Pharmaceuticals Corporation | $46.87 | 2022-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $45.86 | 2022-2023 | Lupkynis |
| Dendreon Pharmaceuticals LLC | $39.43 | 2019-2021 | |
| Welch Allyn | $34.73 | 2021 | |
| Baxter Healthcare | $32.56 | 2022 | |
| Scpharmaceuticals INC. | $32.42 | 2025 | |
| Procept Biorobotics Corporation | $31.42 | 2025 | |
| Outset Medical INC | $29.09 | 2025 | |
| Fresenius USA Marketing, INC. | $28.94 | 2022-2023 | Korsuva, Velphoro |
| Horizon Therapeutics Plc | $28.29 | 2023 | Krystexxa |
| Ambu INC. | $26.72 | 2022-2023 | |
| Abbvie INC. | $22.69 | 2025 | |
| Merck Sharp & Dohme LLC | $18.32 | 2024 | Lynparza |
| Cormedix INC. | $17.72 | 2024 | Defencath |
| Genentech USA, INC. | $15.30 | 2025 | |
| Accord Healthcare, INC. | $15.23 | 2022 | |
| Immunitybio, INC. | $14.34 | 2025 | |
| Janssen Biotech, INC. | $14.26 | 2025 | Erleada |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.65 | 2023 | Jardiance |
| Sumitomo Pharma America, INC. | $13.21 | 2023 | Gemtesa |
| Olympus America INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Namrita Baveja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.